Vir Biotechnology, Inc.·4

Feb 26, 7:34 PM ET

HANLY ANN M. 4

4 · Vir Biotechnology, Inc. · Filed Feb 26, 2024

Insider Transaction Report

Form 4
Period: 2024-02-22
HANLY ANN M.
EVP & Chief Technology Officer
Transactions
  • Sale

    Common Stock

    2024-02-22$10.05/sh12,296$123,521134,780 total
  • Award

    Stock Option (Right to Buy)

    2024-02-22+65,00065,000 total
    Exercise: $10.11Exp: 2034-02-21Common Stock (65,000 underlying)
  • Award

    Common Stock

    2024-02-22+32,500147,076 total
Holdings
  • Common Stock

    (indirect: See footnote)
    11.52
Footnotes (4)
  • [F1]Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
  • [F2]Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
  • [F3]The shares are beneficially owned by the reporting person's spouse, for the benefit of a minor child.
  • [F4]25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter.

Documents

1 file
  • 4
    wk-form4_1708994010.xmlPrimary

    FORM 4